Medicine and Dentistry
Bladder Cancer
100%
Neoplasm
80%
Non Muscle Invasive Bladder Cancer
61%
Transitional Cell Carcinoma
44%
Bladder Tumor
35%
Circulating Tumor DNA
32%
Biological Marker
29%
Muscle Invasive Bladder Cancer
28%
Recurrent Disease
28%
Disease
26%
Cystoscopy
20%
Malignant Neoplasm
17%
Fibroblast Growth Factor Receptor 3
16%
Cystectomy
16%
Metastatic Carcinoma
15%
Urinary System
14%
Bladder
13%
Treatment Response
13%
Cell-Free DNA
12%
Prostate Cancer
12%
Neoadjuvant Chemotherapy
12%
Cisplatin
12%
Carcinoma in Situ
12%
Immunohistochemistry
11%
Cancer Cell
10%
Liquid Biopsy
10%
Disease Exacerbation
10%
Mutational Analysis
9%
DNA Methylation
8%
Gene Expression
8%
Lymph Node Metastasis
8%
RNA Sequence
8%
Gene Expression Profiling
8%
Primary Tumor
8%
Diagnosis
8%
Combination Therapy
7%
Proportional Hazards Model
7%
Methylation
7%
Arm
7%
Hazard Ratio
7%
Cancer Recurrence
6%
Transurethral Resection
6%
Transcriptomics
6%
Tumor Recurrence
6%
Clinical Trial
6%
Risk Stratification
6%
Hematuria
6%
Tamsulosin
6%
Survivin
6%
Exosome
6%
Biochemistry, Genetics and Molecular Biology
Next Generation Sequencing
24%
Cancer Cell
24%
MicroRNA
22%
RNA
20%
Circulating Tumor DNA
16%
APOBEC
16%
Progression Free Survival
14%
Gene Expression
14%
Gene Expression Profiling
14%
Transcriptomics
13%
Messenger RNA
13%
Clinical Trial
12%
RNA Sequence
11%
Carcinogenesis
11%
Transcriptome
11%
Recurrence Free Survival
11%
Bacilli
11%
Urine Sampling
11%
Microarrays
11%
Circular RNA
10%
Allele
10%
Immunostaining
9%
Gene Signature
9%
Germline
8%
Germ Cell
8%
Genetics
8%
Exon
8%
Colon
8%
P53
8%
Prospective Study
7%
Oncogene
7%
Overall Survival
7%
Promoter Region
6%
Immunocompetent Cell
6%
Telomerase Reverse Transcriptase
6%
Tumor Marker
6%
DNA Damage Checkpoint
6%
Chromosome Instability
6%
Karyopherin
6%
Exome
6%
Supernatant
6%
Plasminogen Activator Inhibitor-1
6%
Competing Endogenous RNA
6%
Tissue Microarray
6%
Single-Nucleotide Polymorphism
5%
Transcription Factors
5%
Volume
5%
Droplet Digital Polymerase Chain Reaction
5%
Tumor Volume
5%
Pharmacology, Toxicology and Pharmaceutical Science
Bladder Cancer
65%
Neoplasm
58%
Non Muscle Invasive Bladder Cancer
32%
Biological Marker
24%
Recurrent Disease
23%
Bladder Tumor
20%
Muscle Invasive Bladder Cancer
18%
Malignant Neoplasm
17%
Circulating Tumor DNA
16%
Fibroblast Growth Factor Receptor 3
13%
Transitional Cell Carcinoma
12%
Disease
11%
Chemotherapy
10%
Clinical Trial
7%
Carcinogenesis
7%
Prostate Cancer
6%
Metastasis
6%
Primary Tumor
5%
Transcription Factors
5%
Disease Exacerbation
5%
Carcinoma in Situ
5%